Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

AtriCure Making Progress, But Can It Maximize Value On Its Own?

These are good times for investors to start thinking about putting together shopping lists for speculative healthcare stocks, as the market has been bailing out on not only biotechs but also speculative med-techs. AtriCure (NASDAQ:ATRC) isn't speculative in many important respects, as the company has approvals for its key products, but is still quite speculative insofar as the company's ability to convince doctors to adopt its surgical ablation approach and generate meaningful revenue and profits.

More Progress In The First Quarter

AtriCure continues to log respectable growth in its core businesses. Overall revenue rose 27% in the first quarter, good for a slight beat versus sell-side expectations. U.S. revenue rose 24% as 13% growth in ablation was augmented...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details